A Multi-center, Open Label, Multiple Dose, Phase II Trial to Demonstrate the Safety of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines.

Trial Profile

A Multi-center, Open Label, Multiple Dose, Phase II Trial to Demonstrate the Safety of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Glabellar lines
  • Focus Adverse reactions
  • Acronyms EV-004
  • Sponsors Evolus
  • Most Recent Events

    • 29 Mar 2018 According to an Evolus media release, the company expects a decision on BLA in 2018.
    • 19 Jul 2017 According to an Evolus media release, Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for review of DWP-450, a Botulinum toxin Type A for the treatment of adult patients with glabellar lines (frown lines) between the eyebrows. This BLA is based on the results of EV-001,EV-002, EV-004 and EV-006 clinical trials.
    • 16 May 2017 According to an ALPHAEON Corporation media release, based on the data from EV-001,EV-002, EV-004 and EV-006 trials Evolus Inc. has submitted a Biologics License Application (BLA) for DWP-450, a Botulinum toxin Type A, to the U.S. Food and Drug Administration (FDA) seeking approval for the treatment of adult patients with glabellar lines, also known as "frown lines" between the eyebrows.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top